ClinicaliQ Trial Snapshot
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) — Active Not Recruiting • Phase II • NCT06956235.
- Tulisokibart tested against placebo in moderate-to-severe skin infection; primary outcome was 50% symptom improvement at 16 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment). Conditions: Hidradenitis Suppurativa Interventions: Tulisokibart, Placebo Lead Sponsor: Merck Sharp & Dohme LLC Planned Enrollment: 149 participants